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Abstract
Background: Worldwide, there is concern that increases in the prevalence of dementia will result in large demands
for caregivers and supportive services that will be challenging to address. Previous dementia projections have either
been simple extrapolations of prevalence or macrosimulations based on dementia incidence.
Methods: A population-based microsimulation model of Alzheimer’s and related dementias (POHEM:Neurological)
was created using Canadian demographic data, estimates of dementia incidence, health status (health-related
quality of life and mortality risk), health care costs and informal caregiving use. Dementia prevalence and 12 other
measures were projected to 2031.
Results: Between 2011 and 2031, there was a projected two-fold increase in the number of people living with
dementia in Canada (1.6-fold increase in prevalence rate). By 2031, the projected informal (unpaid) caregiving for
dementia in Canada was two billion hours per year, or 100 h per year per Canadian of working age.
Conclusions: The projected increase in dementia prevalence was largely related to the expected increase in older
Canadians, with projections sensitive to changes in the age of dementia onset.
Keywords: Dementia, Alzheimer disease, Health planning, Computer simulation, Population dynamics, Home care
services, Quality of life, Outcome assessment (Health Care), Health status, Time factors
Research in context
Systematic review
Two main approaches have been used to project the
burden of Alzheimer’s and related dementia: extrapola-
tion of current prevalence, and macrosimulation of dis-
ease incidence and mortality. Microsimulation modeling
has been suggested as an approach to improve dementia
projections.
Interpretation
We present the first, to our knowledge, population
model of Alzheimer’s and related dementia for project-
ing incidence, prevalence, and related outcomes: the
Population Model for Neurological Diseases (POHEM:-
Neurological). POHEM:Neurological projected a demen-
tia burden that was modestly higher than most previous
projections. The microsimulation approach used in this
study offers three benefits: comparisons of people with
dementia to the general population (e.g., the ability to
examine how caregiving for people with dementia will
influence total caregiving); greater specificity (e.g., the
ability to incorporate a range of factors that influence
dementia prevalence); coherent application of a range of
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data (e.g., the same dementia definition and measure of
disease severity to generate a wide range of dementia
outcomes).
Future directions
POHEM:Neurological could be adapted for use in other
jurisdictions. The addition of dementia risk factors could
improve dementia incidence projections. The addition of
these risk factors is feasible, given many risk factors are
the same as those for cardiovascular disease and are in-
cluded in the POHEM:Cardiovascular disease model.
Background
The prevalence of Alzheimer’s and other dementias is
projected to increase considerably in all countries as a
reflection of the world’s aging population [1–4]. The
World Health Organization estimates the global preva-
lence of dementia to be 47.5 million, and this number is
expected to increase substantially in the years ahead,
reaching 135 million by 2050 [4, 5].
The socioeconomic needs that dementia exerts on so-
ciety as a whole has made it a public health priority [6].
Furthermore, there are concerns regarding the potential
increase in the magnitude of dementia prevalence and
the level of care required for each person with dementia
[3, 6]. Population-based dementia models have been cre-
ated to support planning by projecting the number of
people living with dementia and by allowing the examin-
ation of counterfactual scenarios that may ameliorate or
exacerbate dementia’s societal burden.
However, current dementia models have been criticized
as being overly simplistic representations of dementia pro-
gression. Ideally, population models should start from
people who do not have disease and project incident cases,
then move onward to describe disease progression from
mild to more severe disease or to death [3]. However, pre-
vious dementia projections have either been extrapola-
tions of current prevalence trends, which lack incidence
rates altogether, or macrosimulation (cell-based) studies,
which use a constant incidence and mortality rate, among
other simplifying assumptions.
Norton et al. have called for the development of
population-based microsimulation models to address limi-
tations from previous projection models [3]. These au-
thors specifically cite Canada’s Population Health Model
(POHEM) – developed for chronic diseases such as dia-
betes, cardiovascular disease, and arthritis – as an example
of a microsimulation model that more robustly includes
population dynamics (birth, deaths, and migration) and
disease progression (from disease-free to disease with
varying levels of health-related quality of life or health care
use) [7–9]. As well, more complex modeling approaches
have the benefit of synthesizing a wide range of data
sources to generate a more comprehensive viewpoint of
the disease, meaning that microsimulation models provide
insight for complex connected systems [10].
We sought to project the prevalence of dementia and
the related health and health care burden in Canada
from 2011 to 2031 by adapting Canada’s current Popula-
tion Health Model (POHEM) to create a new POHEM:-
Neurological model and supporting software. Using
Statistics Canada’s POHEM framework, we created a
population-based longitudinal microsimulation model
named POHEM:Neurological. The model was created as
part of Canada’s National Population Health Study of
Neurological Conditions (NPHSNC), which included 13
supporting research projects and three national surveys
that examined 13 different neurological conditions [11].
The current project had two goals: i) to project dementia
burden in Canada from a societal perspective that in-
cluded the health impacts as well as direct and indirect
heath care (out-of-pocket costs and informal caregiving),
and ii) to synthesize the wide range of dementia infor-
mation from projects within the NPHSNC.
This study had advisory input from people living with
neurologic conditions, their caregivers, clinicians, and indi-
viduals with policy expertise [11]. The project’s advisors
and research team created the model specification, which
included the model’s purpose, its overall structure, and data
sources. The requested model attributes included the
following:
Population-based – reflecting the Canadian population
including important sub-populations based on factors
such as age, sex, and provincial regions.
Open population – allowing the population to change
over time to reflect historical and projected births,
deaths, immigration, and emigration.
Consistent and coherent – using a consistent definition
of dementia and health-related quality of life (HRQOL)
throughout the model. All outcome measures – from
the onset of dementia to death – are coherently linked
to the definitions of dementia and HRQOL.
Predictive accuracy – able to generate accurate (or
well-calibrated) projections.
Useful for population health planning – can be used to
estimate future dementia burden including direct and
indirect health care costs and caregiver burden.
Flexible and robust – provision to further develop the
model. Risk factors for the development of dementia
were explicitly excluded from the current study.
However, there is provision for the inclusion of risk
factors in future dementia modeling [7].
Methods
Population Health Model (POHEM) framework
Briefly, POHEM is an empirically grounded, longitudinal
microsimulation model of diseases and risk factors
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representing the lifecycle dynamics of the Canadian
population [12, 13]. The basic unit of analysis is individ-
ual people, or “actors,” whose life course is modeled in
continuous time using a Monte Carlo approach. The dy-
namic simulation recreates the Canadian population at a
given point in time (both historically and in the future)
and ages it, one actor at a time, until each actor’s death.
Model development
Figure 1 shows the four steps that make up the process
of microsimulation model development: initialization,
yearly updates, model validation, and projection. Canad-
ian population-based data sources were used throughout
the model (see Additional file 1).
Initialization
POHEM:Neurological was initialized using the same ap-
proach that was used for POHEM cancer modeling
(called OncoSim) [14]. The purpose of model
initialization was to create model “actors” to reflect the
Canadian population, both historic observations and fur-
ther population growth projections [15].
Initialization began with historic birth cohorts from
1872, which were subject to observed historic death
rates. Migration (immigration and emigration) was
added to the birth cohorts, also reflecting the historic
observed or estimated events. The birth cohorts used
observed data up to 2006, with projected births, deaths,
and migration that followed standard Canadian popula-
tion projections (mid-growth scenario), as estimated by
Statistics Canada [15]. High- and low-growth scenarios
were used in sensitivity testing (described later).
Yearly updates of actors’ health profiles
An actor’s health profile consists of six main characteris-
tics: (i) demographics (e.g., age, province of residence);
(ii) dementia status; (iii) health status; (iv) presence of an
informal caregiver; (v) health care costs; and (vi) mortal-
ity (date of death). Each actor’s health profile was up-
dated throughout the year, either at the occurrence of an
event (e.g., birthday, date of diagnosis of dementia) or at
Fig. 1 Process for Population Health Model (POHEM):Neurological
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the change of the calendar year, depending on the profile
characteristic. All health profile characteristics were cal-
culated and modeled for people with and without de-
mentia (see Additional file 1 for data sources).
Dementia status: incidence, prevalence and mortality
Two steps were followed to generate prevalent dementia
actors. First, sex- and age-specific dementia incidence
rates were applied to the model’s synthetic Canadian
population for each year, both historical and projected.
Dementia incidence rates were estimated using a case
definition algorithm with a sensitivity of 79.3 % and spe-
cificity of 99.1 % among individuals age 65 years and
older (see Additional file 1 for ascertainment diagnostic
codes, algorithm, and incidence rates), [16, 17] and ap-
plied to administrative health data from the province of
British Columbia. Actors where classified as being diag-
nosed with dementia based on each actor’s risk of devel-
oping dementia at the beginning of each calendar year.
Incident dementia cases accumulated over time to gen-
erate prevalent cases of dementia.
Second, dementia-specific mortality risk was applied
to actors with dementia. The dementia mortality risk
was a product of a mortality ratio for people with de-
mentia multiplied by the baseline mortality rate for the
Canadian population within POHEM. The general popu-
lation’s mortality rate gradually decreased over time,
reflecting the projected mortality (life expectancy) using
birth cohorts and the Lee-Carter model as estimated by
Statistics Canada [18]. This means that the projected
mortality for people with dementia decreased at the
same rate as for Canadians living without dementia. The
mortality hazard ratio for people with dementia was esti-
mated using the same case definition and data used to
estimate dementia incidence.
Health status
The Health Utilities Index Mark 3 (HUI3) is a utility-
based measure that reflects health states ranging from
perfect health (HUI3 = 1.0) through death (HUI3 = 0),
including states considered to be worse than death
(minimum HUI3 = -0.36), thereby allowing a wide
range of severity levels and applications [19]. The
HUI3 was used because: i) there is a consistent use
of the HUI3 across many Canadian dementia data
sources; and ii) the HUI3 is routinely measured for
Canadians without dementia, including the general
population and people with other chronic disease,
thereby allowing an assessment of the incremental
burden of dementia and/or counterfactual scenarios.
See Fig. 2 for age-specific mean HUI3 for people with
and without dementia.
Informal caregivers
At the end of every calendar year, the likelihood that an
actor would receive informal caregiving for the following
year was based on the actor’s age, dementia status, and
health status (HUI3). If an actor was assigned the pres-
ence of an informal caregiver, additional characteristics
were also assigned: (i) hours of care received; (ii) health
status of their caregiver; and (iii) out-of-pocket expenses
incurred by caregivers.
Health care costs
The health care costs included formal health care
costs, out-of-pocket costs, and informal care by care-
givers (hours of care per week). Formal health care
costs were examined for seven health sectors: (i)
hospitalization; (ii) physician services; (iii) prescription
drugs; (iv) rehabilitation hospitals; (v) formal (paid)
home care; (vi) residence and care in a long-term
care facility; and (vii) assistive devices. Formal health
costs were based on whether an actor was an incident
case (within the first 12 months following incidence)
or prevalent case (one year or more since incidence)
of dementia. Out-of-pocket expenses were those not
covered by private insurance or provincial health care
plans, such as the cost of prescription and over-the-
counter medications, assistive devices, rehabilitation
therapy such as physical or occupational therapy,
home care services. See Additional file 1 for details.
Validation
Model validation focused on calibration and was per-
formed by comparing projected to observed estimates
for a given calendar year [20, 21]. We compared the pro-
jected estimates of dementia prevalence and deaths to
the rates observed in British Columbia in 2009, the same
province in which the age and sex-specific dementia in-
cident rates were estimated. Validating model-predicted
estimates against an external reference population was
the preferred approach of assessing predictive accuracy
of the baseline model [20, 21]. While the British Colum-
bian population did not meet the criteria of an external
population, the generated predictions were estimated
using a series of historic birth cohorts, which was a con-
siderably different approach than what was used to esti-
mate dementia prevalence using administrative data.
The model initialization showed uncalibrated estimated
dementia prevalence that closely approximated the ob-
served age- and sex-specific prevalence in 2009 (see
Additional file 1); therefore calibration was unnecessary.
Projection
Model parameters were projected through 2031 and be-
yond, including: (i) incident and prevalent dementia
cases in Canada; (ii) years of life lost (YLL) with
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dementia; (iii) health-adjusted life years lost (HYLL); (iv)
direct health care costs – including costs for each of the
seven sectors; (v) out-of-pocket expenses; and (vi) hours
of informal caregiving. In addition, three parameters
were projected from the perspective of caregivers for de-
mentia: (i) hours of caregiving; (ii) out-of-pocket ex-
penses; and (iii) health status (HUI3).
YLL was defined as the difference between the age
of death of an actor with dementia compared to the
age of death if that actor did not develop dementia.
To obtain the latter, we set the relative mortality haz-
ard for dementia to 1.0 and recalculated age of death:
YLL was the difference in age of death between the
two calculations. HYLL was calculated in a similar
manner, with health-adjusted life years estimated from
the product of years of life lived (i.e., age of death)
multiplied by the annual HUI3 for each actor over
their lifetime.
Sensitivity analyses were performed to examine the in-
fluence of different model parameters on the projected
burden of dementia. These included: (i) high and low
projected Canadian life expectancy, as per Statistics
Canada population projections; [15] (ii) delayed demen-
tia onset (lower dementia incidence); and (iii) lower risk
of dementia death.
Microsimulation model and statistical analyses
The POHEM model was generated using MODGEN
(Model Generator), a microsimulation programming




At baseline in 2011, there were 340,000 people living
with dementia in Canada, a number which was projected
to approximately double to 674,000 people by 2031
(1.98-fold increase) (Table 1). There was a smaller in-
crease in the prevalence rate for older people (e.g., age
80 years and older) compared to younger people (1.06-
fold increase by 2031 versus 1.55-fold increase), a reflec-
tion of the overall aging of the Canadian population.
When evaluating the burden of dementia, the most
sensitive model parameter for dementia prevalence pro-
jection was dementia incidence. When dementia inci-
dence was delayed by 5 years, there was only a 1.10-fold
increase in dementia cases (374,000 people projected to
be living with dementia in 2031) as opposed to the 1.98-
fold increase projected by the base model. Changes to
the projected Canadian life expectancy (affecting those
with and without dementia) had a modest impact on de-
mentia projections, with only a small increase in the
projected number of people living with dementia in
2031 under a high life expectancy scenario (2.08-fold in-
crease in people living with dementia). Improved (de-
creased) relative mortality for people living with
dementia had a similar modest increase in dementia
projections, with a 10 % decrease in the dementia-
specific mortality rate resulting in a 2.09-fold increase in
dementia prevalence by 2031.
Projected health burden
Table 2 shows the projected health burden of dementia.
The projected number of deaths among people with
Fig. 2 Health status (Health Utilities Index Mark 3) for people with and without dementia, Canada, 2011
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dementia increased from 2011 to 2031 at a somewhat
lower rate than the increase in dementia prevalence
(1.70-fold increase in the number of dementia deaths
compared to 1.98-fold increase in the number of people
living with dementia). The relatively smaller increase in
the number of deaths was a consequence of a projected
decrease in mortality for the general population, which
itself resulted in a decrease in the death rate among
people with dementia (146 deaths/1000 people in 2011
versus 125 deaths/1000 people in 2031). For persons
with dementia who died in 2011, there were 3.4 YLL
and 3.3 HYLL: extrapolated to the population level, 1.2
million YLLs and 1.1 million HYLL were lost due to de-
mentia. There was a modest projected reduction of YLL
and HYLL by 2031.
For people living with dementia in 2011, 77 % were es-
timated to be receiving informal care (261,000 people),
with less than a 1 % projected increase in the proportion
receiving care by 2031. The small change was a reflec-
tion of model assumptions, namely that the factors
Table 1 Dementia prevalence (cases per 1000 people), Canada, 2011 to 2031, by sex
2011 Baseline Sensitivity analyses, ratio (2031:2011)
2031 Ratio (2031:2011) Higher Canadian life expectancya Decreased dementia mortalityb Delayed incidencec
Number of people with dementia
Total 340,000 674,000 1.98 2.08 2.09 1.10
Males 142,000 291,000 2.05 2.16 2.15 1.13
Females 198,000 383,000 1.93 2.02 2.04 1.07
Prevalence rate (per 1000 people)
Age 40 years and older
Total 20.0 31.0 1.55 1.61 1.63 0.85
Males 17.3 27.6 1.60 1.67 1.68 0.88
Females 22.5 34.1 1.52 1.57 1.59 0.83
Age 80 years and older
Total 177 187 1.06 1.08 1.12 0.62
Males 171 182 1.06 1.09 1.12 0.62
Females 180 191 1.06 1.08 1.12 0.61
aHigher life expectancy based on projections by Statistics Canada
b10% lower mortality hazard among those with dementia, relative to baseline relative mortality hazard
cDelay age-specific incidence of dementia by 5 years, relative to baseline incidence rates
Table 2 Projected burden and informal caregiving for people living with dementia, Canada, 2011 to 2031
2011 Baseline scenario, 2031 Decreased dementia mortalitya, 2031 Delayed incidenceb, 2031
Estimate Ratio Estimate Ratio Estimate Ratio
Number of people with dementia 340,000 674,000 1.98 709,000 2.09 374,000 1.10
Deaths 50,000 85,000 1.70 83,000 1.66 52,000 1.04
Mortality rate (deaths/1000) 146 126 0.86 118 0.81 138 0.95
Years of life lost 3.4 3.2 0.96 2.9 0.86 2.9 0.87
Health-adjusted years of life lost 3.3 3.2 0.98 3.2 0.97 2.9 0.88
Informal care
People receiving care 261,000 522,000 2.00 552,000 2.11 291,000 1.11
Hours per year (millions) 1,000 2,000 2,100 2,100 1.13 1,130 1.13
Hours per year (per person age 25 to 65 years) 52.3 100.4 106.5 106.5 1.08 56.6 1.08
Receiving no care (%) 23.2 22.5 0.97 22.2 0.96 22.0 0.95
Less than 7 h/week (%) <0.1 <0.1 1.34 <0.1 1.28 <0.1 1.03
7 to 14 h/week (%) 0.1 0.1 1.02 0.1 0.97 <0.1 0.77
15 to 70 h/week (%) 26.5 26.3 0.99 26.0 0.98 24.3 0.92
71 or more hours/week (%) 50.3 51.1 1.02 51.7 1.03 53.6 1.07
a10% lower mortality hazard among those with dementia, relative to baseline relative mortality hazard
bDelay age-specific incidence of dementia by 5 years, relative to baseline incidence rates
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affecting the receipt of care (i.e., HUI3 values) did not
change over time in our model. However, the total num-
ber of people with dementia receiving care was projected
to increase 2-fold to 522,000 in 2031, reflecting the in-
crease in the number of people living with dementia.
There was a corresponding increase in the number of
caregiving hours; in 2031, a projected 2.0 billion infor-
mal caregiving hours were utilized by persons with de-
mentia. The caregiving hours per working-age person
(ages 25 to 65 years) were projected to increase from
52.3 to 100.4 h per week.
Projected health care use
Table 3 shows that the direct health care cost for people
with dementia was $9.2 billion CDN in 2011 ($27,000
per-person cost), which was projected to increase to
$18.2 billion in 2031. In sensitivity analysis, the 2031
costs varied from $10.3 billion with a delay in dementia
onset to $19.2 billion with a reduction in dementia mor-
tality hazard. The highest cost sectors were long-term
care (46 % of total cost) and hospitalization (27 % of
total cost).
Discussion
We created a population-based microsimulation model
of dementia in Canada and projected 13 health and
health care outcomes for people living with and without
dementia. Using a single unified model, it is possible to
estimate and project most measures in typical national
reports such as the United States Alzheimer’s disease
facts and figures [23].
We found that, between 2011 and 2031, the burden of
dementia for most outcomes was projected to approxi-
mately double. By 2031, the number of hours of informal
care per person (per Canadian of working age, 25-65
years) was projected to be 100 h per year, or approxi-
mately 2.7 h per workweek (at 37.5 h per week).
Current study in perspective
To our knowledge, this is the first population-based
microsimulation projection of dementia. That stated,
microsimulation methods have been used to estimate
current population and individual lifetime cost [24, 25].
As in most other studies, we found that the burden of
dementia was projected to increase substantially as a
consequence of an “aging” population, meaning a popu-
lation with a higher proportion of older people com-
pared to younger people [2, 3, 26]. However, our study’s
projections showed a more rapid increase compared to
projected increases in other developed countries, where
dementia is projected to increase by 40 % in Europe and
63 % in North America within a 20-year period [26].
Without a detailed comparison of studies, it is difficult
to identify why we project a more rapid increase in de-
mentia. Potential differences in models may relate to
underlying demographic changes, dementia-specific
mortality, or differences in dementia incidence. Differ-
ence in the demographic projections likely contributed
to important differences in the projected increase in de-
mentia in our study compared to projections in the
United States and Europe. For example, no other de-
mentia model, to our knowledge, has considered how
all-cause or dementia mortality will change over time.
The expected decrease in both all-cause and dementia
mortality will increase survival time for people living
with dementia and thus increase projected prevalence.
Mortality projections for dementia in our study started
with mortality projections for the general Canadian
population that used a well-established method used by
national statistical agencies [15, 18]. The relative mortal-
ity hazard of dementia was calculated using the same de-
mentia ascertainment approach that was used to
estimate dementia incidence.
In our study, dementia incidence (or age of dementia
onset) was shown to have a strong influence in the pro-
jected increase in the rate of dementia. However, the ap-
proach and assumptions of assessing dementia incidence




Baseline Decreased dementia mortalitya Delayed incidenceb
Physician services 728 1,440 1,510 798
Hospitalization 2,560 5,000 5,210 2,790
Drug 1,000 2,000 2,100 1,090
Rehab 85 169 180 96
Assistive devices 80 160 170 90
Home care 580 1,160 1,220 646
Long-term care 4,160 8,300 8,830 4,740
Total cost 9,200 18,210 19,210 10,250
a10% lower mortality hazard among those with dementia, relative to baseline relative mortality hazard
bDelay age-specific incidence of dementia by 5 years, relative to baseline incidence rates
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should not influence the rate of dementia increase. We
used a definition of dementia that relied on physician-
coded diagnoses in health administrative data, whereas
many other studies and most reviews of dementia preva-
lence used a broader definition of dementia that in-
cluded undiagnosed dementia cases [26]. Differing
ascertainment approaches will affect the absolute level of
dementia prevalence but not the rate of increase of de-
mentia, unless there is a change in the proportion of
cases that are diagnosed. Approximately 30 % of demen-
tia cases in Canada are not diagnosed, and the identifica-
tion approach using administrative (with imperfect
sensitivity) will further under-ascertain dementia by
10 % [27]. The definition of diagnosed dementia in our
study allowed for a coherent assessment of burden for
all dementia outcomes including mortality, health status
(disease severity), and health care use (both formal and
informal care), and reflected the preferences of the
study’s advisory panel. Furthermore, the ascertainment
approach is widely used in Canada for chronic disease
surveillance, including within the larger (Canadian) Na-
tional Population Study of Neurological Conditions, as
well as the Public Health Agency of Canada’s Canadian
Chronic Disease Surveillance System. A lack of dementia
diagnosis coherence in modeling studies can result is
poor calibration when, for example, one definition is
used for disease incidence but mortality risk is estimated
using a different definition.
Lastly, dementia prevalence varies considerably be-
tween studies depending on whether the rate is reported
for all ages or for specific age cutoffs. Care is required
when comparing projected prevalence between studies
to ensure the same age groups are considered. Studies
that report dementia for only older ages will generally
report higher rates of dementia increase compared to
studies that project total dementia. We present the full
age pyramid in Fig. 3 to provide insight into the pro-
jected Canadian population structure and how it will in-
fluence the number of people with dementia.
The microsimulation population approach has several
additional advantages over previous modeling ap-
proaches. First, within POHEM:Neurological there are
the same health and health care outcomes for people
with and without dementia, including people with other
chronic conditions. This population perspective builds
on our existing understanding of health for the entire
population and allows for a comparison with people
without dementia or other chronic diseases. Second, a
microsimulation approach allows for greater breadth
and complexity compared to other modeling strategies.
We included a wide range of health outcomes, which al-
lows for a more comprehensive understanding of the
burden of dementia. The greater complexity also allows
for a more realistic representation of dementia burden.
For example, we examined caregiving use and out-of-
pocket expenses that varied by age, sex, and health sta-
tus (HUI3).
As previously stated, the data consistency of the de-
mentia model was a strength. In addition to a consistent
case definition of dementia, we also used a consistent
health status or disease severity measure, the HUI3,
across different data sources for both people with de-
mentia and their caregivers.
POHEM:Neurological also has limitations. As models
become increasingly complex, they become difficult for
users to fully understand, leading to a common concern
that they seem like “black boxes” which are difficult to
assess [10]. These concerns are well-founded. However,
POHEM facilitates transparency using several ap-
proaches. First, the predictive accuracy of model esti-
mates can be validated. Validation is usually performed
with a historic “wash in” period that compares model-
predicted estimates to observed estimates. We found
that model-projected prevalence using historic data
closely approximated observed prevalence. Second, the
assumptions in POHEM:Neurological can be assessed.
Many dementia projections are extrapolations of historic
prevalence trends [3]. Extrapolations are simple and in-
tuitive – and thereby appear to be easy to understand.
However, extrapolation combines so many factors that it
can be difficult to understand what influences their pro-
jected estimates. By comparison, POHEM:Neurological
generates prevalence estimates combining population
growth parameters (migration, births, deaths), dementia
incidence, and dementia deaths. Each parameter can be
examined and/or modified separately.
Currently, dementia projection models, including
POHEM:Neurological, do not consider preventable risk
factors. Norton et al. recommended that predictive
microsimulation models be used for population-based
dementia projections, in part because microsimulation
models are well-suited for inclusion of dementia risk fac-
tors. Norton et al. singled out the POHEM family of
microsimulation models because the modeling frame-
work already includes projections of most well-
established preventable risk factors for dementia [3]. For
example, Barnes and Yaffe estimated that 50 % of Alz-
heimer’s disease is attributable to diabetes, hypertension,
obesity, depression, physical activity, smoking, and low
education [28]. Currently, the cardiovascular disease
module of POHEM includes and projects all of these
risk factors except depression. However, we felt that
more development studies are required to understand
the predictive nature of these risk factors on dementia
incidence.
Lastly, a limitation of the study is the lack of confi-
dence or uncertainty intervals of model estimates. In lieu
of uncertainty estimates, we performed sensitivity
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analyses of the main model parameters and found
that dementia incidence and age of diagnosis had a
strong influence on prevalence. As well, we present
the distribution of informal caregiving hours received
(Table 2) to demonstrate how model projections using
a microsimulation approach can readily include distri-
butions of model inputs and/or outputs. The ap-
proach to estimate uncertainty in models has not
been well established, but there is recognition that it
should include concepts of statistical error, uncer-
tainty from model specification and approach, and the
distribution of model parameters [21]. In the era of
models generated from large data, such as POHEM:-
Neurological, most important uncertainty likely origi-
nates from model specification and distribution of
model parameters.
Conclusions
To our knowledge, this study is the first to project de-
mentia using a microsimulation model. Microsimulation
models of dementia have the potential to produce im-
proved estimates for planning. We projected a more
rapid increase in dementia prevalence by including pro-
jections of underlying all-cause mortality rates. The
microsimulation framework more readily allows for mul-
tiple dementia outcomes. For example, this study is the
first, to our knowledge, to project the need for caregiv-
ing, based on projections of dementia prevalence and
disease severity. In addition, we project a wide range of
outcomes not previously reported, including health care
costs by sector and health-adjusted life years lost. Micro-
simulation models are also well-suited for scenario test-
ing. It appears that prevention could play an important
Fig. 3 Canadian population and proportion of people with dementia
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role in reducing dementia burden, given the strong influ-
ence of delaying disease incidence.
The POHEM:Neurological model shows that it is feas-
ible to develop a well-calibrated population-based micro-
simulation model of dementia that provides a robust
framework for further development and application for
planning. POHEM:Neurological could be used by other
jurisdictions by replacing model parameters such as
Canadian dementia incidence.
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Additional file 1: Details of data sources. (PDF 268 kb)
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